Parkinson's Disease (PD) Model based In Vitro Assay Services

Parkinson's disease (PD) is a neurodegenerative disease pathologically characterized by the loss of dopaminergic neurons in the substantia nigra and proteinaceous amyloid fibrils composed mostly of α-synuclein, called Lewy pathology. These accumulations of alpha-synuclein appear to spread from one neuron to the next. As the number of Lewy bodies increases in the brain and in the nervous system in the body, the symptoms of PD worsen. At Creative Biolabs, we are dedicated to supporting a range of PD research and therapeutic developments. We offer a comprehensive range of in vitro, in vivo and ex vivo assays tailored to meet your specific needs. Our standard and customizable models enable efficient screening of potential therapeutic compounds. Additionally, we provide detailed project reports to facilitate the advancement of your PD research.

Available Models Available Assays

Available In Vitro Models

We provide a comprehensive range ofin vitro models that faithfully recapitulate key aspects of PD pathology.

Fig. 1 Generation and characterization of iPSC-derived astrocytes from PD patients. Fig.1 Generation and characterization of iPSC-derived astrocytes from PD patients. ICC images show astrocytes from two Ctrl iPSC lines and three PD iPSC lines that express CD44, GFAP, S100β, and GLT1, but not TUJ1, MAP2, or NG2.¹

Cell models	Details
Induced pluripotent stem cells (iPSCs)	We generate individualized hiPSC models using PD patient samples, by utilizing these patient-specific models, researchers gain invaluable insights into genetic factors and cellular pathways underlying PD pathology. This platform serves as a robust foundation for investigating the disease's etiology and evaluating the efficacy of potential therapeutic interventions.
In vitro primary culture	The primary neuronal cells are directly isolated and cultured from the midbrain of the mouse fetus at embryonic day 14 to 18. The cultured cells undergo treatment with a neurotoxin, effectively establishing an in vitro cell model for PD assays.
Organotypic cultures	Organotypic cultures can mimic in vivo cell interactions and tissue organization in vitro. Thebrain slices can replace time-consuming animal experiments, provide precise readouts, and are valuable tools for screening potential therapeutic compounds for PD in vitro.
Cell lines	SH-SY5Y: The SH-SY5Y cell line exhibits numerous characteristics with dopaminergic neurons, and both undifferentiated and differentiated SH-SY5Y cells have been widely employed as cell models for PD. Leveraging this cell model offers significant advantages for preliminary PD investigation, including reliable and consistent readouts, coupled with cost-effectiveness. MEs23.5: MEs23.5 cells represent a novel dopaminergic cell strain derived through cell fusion techniques using the mouse neuroblastoma glioma cell line N18TG2 and rat midbrain cells. This innovative cell line is instrumental in establishing in vitro assays for screening drugs for PD treatment. By combining the advantages of both cell types, MEs23.5 cells stand out as the optimal choice for developing in vitro assays to screen drugs for PD treatment. MN9D: MN9D cells are derived from the fusion of the mouse neuroblastoma glioma cell line N18TG2 with dopa femoral nerve cells from the embryonic mouse midbrain tectum. This cell line serves as a valuable tool for investigating both dopaminergic neuron injury models and the mechanisms underlying dopaminergic neuron loss and PD.

Available PD In Vitro Services

Creative Biolabs offers a wide range of in vitro assays that enable researchers to better understand PD progression and evaluate optimized treatments for PD.

Alpha-Synuclein Aggregation Assay	Microglia Activation Assay
MPP⁺ Neuronal Cell Death Assay	GBA Mutation Assay
α-Synuclein Degrader Compound Screen Assay

Creative Biolabs offers PD in vitro modeling and assays to assist you speed up your PD research. Please contact us for further information so that you can make better decisions sooner.

References

di Domenico, Angelique et al. "Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease." Stem cell reports vol. 12,2 (2019): 213-229. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only. Not For Clinical Use.

Related Section

Alpha-Synuclein Aggregation Assay

Microglia Activation Assay

MPP⁺ Neuronal Cell Death Assay

GBA Mutation Assay

α-Synuclein Degrader Compound Screening Assay

In Vitro Services

Webinar

Hot Products

Antibodies

Cells

Kits

Tracers

Gene Therapy Tools

Biospecimens

Cell Assay Reagents